A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

NCT ID: NCT05405725

Last Updated: 2022-08-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 504 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-04
• Study Completion Date: 2024-08-31

Brief Summary

This is a phase 3 Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis

Conditions

Postmenopausal Osteoporosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

ENZ215

ENZ215 Injection:- 60 mg Denosumab (ENZ215) will be administered subcutaneously on day 1.

Group Type: EXPERIMENTAL

ENZ215

Intervention Type: BIOLOGICAL

Enrolled women with postmenopausal osteoporosis will receive ENZ215 (60mg)

Prolia

Prolia Injection:- 60 mg Denosumab (Prolia) will be administered subcutaneously on day 1.

Group Type: ACTIVE_COMPARATOR

Prolia

Intervention Type: BIOLOGICAL

Enrolled women with postmenopausal osteoporosis will receive Prolia

Interventions

ENZ215

Enrolled women with postmenopausal osteoporosis will receive ENZ215 (60mg)

Intervention Type: BIOLOGICAL

Prolia

Enrolled women with postmenopausal osteoporosis will receive Prolia

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Willing to provide voluntary written informed consent and able to comply with the protocol requirements

2. Postmenopausal women aged ≥ 55 and ≤ 85 years

3. Body weight ≥ 50 kg and ≤ 90 kg

4. Diagnosed with osteoporosis, with absolute BMD at the lumbar spine (L1-L4 region) as measured by dual-energy X ray absorptiometry (DXA) at screening

5. At least 5 years of postmenopausal status confirmed by follicle-stimulating hormone (FSH) levels at screening

6. At least one hip joint and two vertebrae in L1-L4 region evaluable by DXA

7. No other clinically significant medical history, vital signs, physical examination, laboratory profiles as deemed by the Investigator or designee

Exclusion Criteria

1. Known hypersensitivity to denosumab or any of the excipients of the study drug

2. Known intolerance to, or malabsorption of calcium or vitamin D supplements

3. Previous exposure to Prolia® or any other denosumab biosimilar

4. Previous use of oral bisphosphonates

5. Use of intravenous bisphosphonates within the past 5 years prior to screening

6. Use of parathyroid hormone or its derivatives, systemic hormone replacement therapy, selective estrogen-receptor modulators, or tibolone or calcitonin within 12 months prior to enrollment

7. Any prior use of fluoride or strontium

8. Systemic glucocorticoids (≥ 5 mg prednisone equivalent per day or cumulative dose ≥ 50 mg) for more than 10 days within 3 months prior to enrollment (topical and inhaled corticosteroids are allowed)

9. Other bone active drugs (i.e. drugs affecting bone metabolism) including heparin, anti-epileptics (except for benzodiazepines and pregabalin), systemic ketoconazole, adrenocorticotrophic hormone (ACTH), lithium, protease inhibitors, gonadotropin-releasing hormone (GnRH) agonists, or anabolic steroids within the past 3 months prior to screening

10. Known sensitivity to drug products derived from mammalian cell lines

11. History of one severe or more than two moderate vertebral fractures per Genant classification as determined by the central reading center

12. History of hip fracture or bilateral hip replacement

13. Total hip or femoral neck T-score <-4.0

14. History and/or presence of atypical femoral fracture

15. Presence of any active healing fracture according to the Investigator's assessment

16. History of any transplant or chronic immunosuppression (including patients on immunosuppressive therapy)

17. Severe liver dysfunction

18. Positive testing for hepatitis B (hepatitis B virus surface antigen [HbsAg]) or hepatitis C (hepatitis C virus antibody [HCV Ab]) virology

19. Known history of human immunodeficiency virus (HIV) infection or positive serology for HIV at screening

20. Significantly impaired renal function or receiving dialysis

21. Oral or dental conditions

22. Major surgery within 8 weeks prior to screening or anticipated major surgery during the study

23. Clinically significant leukopenia, neutropenia, or anemia as determined by the Investigator or any other clinically significant medical condition or laboratory abnormality that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with adherence to study procedures, study completion, or the interpretation of study results

24. Patient with an active infection or history of infection

25. Suspected signs and symptoms of COVID-19/confirmed COVID-19 or with recent history of travel/contact (less than 2 weeks from screening) with any COVID-19 positive patient/isolation/quarantine

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Alkem Laboratories Ltd

INDUSTRY

Sponsor Role: collaborator

Enzene Biosciences Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

MEDICAL PLUS s.r.o.

Uherské Hradiště, , Czechia

Site Status: RECRUITING

Countries

Czechia

Central Contacts

Dr. Harish Shandilya

Role: CONTACT

harish.shandilya@enzene.com

+9102067184202 ext. 4202

Facility Contacts

Eva Dokoupilova

Role: primary

Other Identifiers

ALK22/ENZ215-DEN2

Identifier Type: -

Identifier Source: org_study_id